SBI Securities’s Karyopharm Therapeutics KPTI Stock Holding History

SBI Securities’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$655	Hold	67	–	–	﹤0.01%	2944
2026 Q1	$373	Sell	67 -7	-9%	-$53	﹤0.01%	2998
2025 Q4	$545	Hold	74	–	–	﹤0.01%	2844
2025 Q3	$484	Hold	74	–	–	﹤0.01%	2982
2025 Q2	$319	Hold	74	–	–	﹤0.01%	3151
2025 Q1	$277	Buy	74 +26	+54%	+$222	﹤0.01%	3103
2024 Q4	$485	Buy	+48	New	+$580	﹤0.01%	2900

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SBI Securities's KPTI Position: Q2 2026 in Review

SBI Securities held its Karyopharm Therapeutics (KPTI) position steady in Q2 2026 at 67 shares worth $655. The position accounts for ﹤0.01% of the portfolio, ranked #2944.

SBI Securities first reported a position in KPTI in Q4 2024 and has held it in 7 quarters since. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

SBI Securities held 67 shares of Karyopharm Therapeutics worth $655 as of Q2 2026.
SBI Securities left its Karyopharm Therapeutics share count unchanged in Q2 2026.
Karyopharm Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2944 holding.
SBI Securities first reported a position in Karyopharm Therapeutics in Q4 2024 and has held it in 7 quarters since.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.